Monday, November 9, 2026

Dow Jones Bullish Momentum: 1.1% Up Since The Last Session

ViaNews Editorial Team

January 6, 2021

Dow Jones Bullish Momentum: 1.1% Up Since The Last Session

Dow Jones is currently on bullish momentum. At 10:27 EST on Wednesday, 6 January, Dow Jones is at $30,726.36, 1.1% up since the last session's close.

Dow Jones Range

Dow Jones is 1.939% up from its last session low of $30,141.80 and 0.726% up from its last session high of $30,504.90.

Over the last three sessions, Dow Jones's higher value was $30,674.30 and the lower value was $29,881.80.

Over the last seven sessions, Dow Jones's higher value was $30,674.30 and the lower value was $29,881.80.

Over the last month, Dow Jones's higher value was $30,674.30 and the lower value was $29,755.50.

Concerning Dow Jones's yearly highs and lows, it's 68.699% up from its 52-week low and 0.118% down from its 52-week high.

Volatility

Dow Jones's last day, last week, and last month's average volatility was a positive 0.55%, a negative 0.01%, and a positive 0.07%, respectively.

Dow Jones's last day, last week, and last month's high and low average amplitude percentage was 1.20%, 1.26%, and 0.99%, respectively.

Last news about Dow Jones

S&P dow jones says it will cancel deletion of China telco adrs. According to Bloomberg Quint on Wednesday, 6 January, "S&P Dow Jones Indices said it will no longer delete the U.S.-listed shares of three Chinese telecom firms from its benchmarks, a move that was set to take effect on Thursday.", "S&P Dow Jones said it had no comment on the possibility that NYSE will reverse course yet again."

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cycle: Data Readouts, FDA Decisions and Capital-Allocation Shifts
From late October to January, mid-cap biotechs move through a dense run of events: ESMO and AHA/AASLD data presentations, Q3 earnings, and FDA PDUFA dates for ivonescimab (Nov 14) and lorundrostat (Dec 22). Alongside the regulatory news, companies are changing how they allocate capital: one lowered FY2026 R&D and SG&A guidance and pushed milestones into 2027, one authorized a $400M buyback, and one scheduled a delisting vote (EGM Nov 19, application Jan 25). Value is concentrating in a few binary regulatory and Phase 3 outcomes (Maritime-1 and ECLIPSE 2/3 readouts around Q1 2027), so sentiment is mixed.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,558 source documents archived
Query this data → isubstrate.com